Business Context and Reporting Period
This Form 8-K Current Report was filed by Intellia Therapeutics, Inc. on June 12, 2024. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
Material Changes
The material change reported is the appointment of Brian Goff as a Class I director, effective June 13, 2024. Mr. Goff was also appointed to the Compensation and Talent Development Committee. The Board determined Mr. Goff is independent under Nasdaq listing rules.
Compensation and Governance Details
- Director Background: Mr. Goff brings over three decades of experience in commercialization and operations, most recently serving as CEO of Agios Pharmaceuticals since 2022.
- Compensation Package: As a non-employee director, Mr. Goff will receive cash compensation per the company's program. Additionally, he was granted:
- An option to purchase 22,297 shares of common stock at an exercise price of $25.96 per share.
- 15,409 restricted stock units (RSUs).
- Vesting Schedule: Awards vest 33 1/3% one year after the grant date, followed by substantially equal quarterly installments over the subsequent two years, contingent on continued service. Full exercisability occurs upon a change in control.
- Indemnification: Mr. Goff will enter into the Company's standard indemnification agreement.
Investor Verification Checklist
- Verify the independence status of Brian Goff under current Nasdaq listing rules.
- Review the specific terms of the non-employee director compensation program referenced in the filing.
- Confirm the vesting schedule and exercise price details for the 22,297 stock options and 15,409 RSUs granted.
- Check for any potential conflicts of interest given Mr. Goff's recent role as CEO of Agios Pharmaceuticals.